Amodiaquine analogues containing NO-donor substructures: Synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria by Massimo, Bertinaria et al.
1 
 
 
 
This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here by 
agreement between Elsevier and the University of Turin. Changes resulting from the publishing process 
- such as editing, corrections, structural formatting, and other quality control mechanisms - may not be 
reflected in this version of the text. The definitive version of the text was subsequently published in 
[European Journal of Medicinal Chemistry 46 (2011) 1757e1767, 22 February 2011, 
doi:10.1016/j.ejmech.2011.02.029]. 
 
You may download, copy and otherwise use the AAM for non-commercial purposes provided that your 
license is limited by the following restrictions: 
 
(1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND 
license.  
(2) The integrity of the work and identification of the author, copyright owner, and publisher must be 
preserved in any copy.  
(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en), [+ Digital Object Identifier link to the 
published journal article on Elsevier’s ScienceDirect® platform]  
 
2 
 
 
Amodiaquine analogues containing NO-donor substructures: synthesis and their preliminary 
evaluation as potential tools in the treatment of cerebral malaria 
 
Massimo Bertinaria
a,†
, Stefano Guglielmo
a,†
, Barbara Rolando
a
, Marta Giorgis
a
, Cristina Aragno
a
, 
Roberta Fruttero
a
, Alberto Gasco
a,* 
, Silvia Parapini
b
, Donatella Taramelli
b
, Yuri C. Martins
c
, 
Leonardo J. M. Carvalho
c
 
 
a
Dipartimento di Scienza e Tecnologia del Farmaco, Via P. Giuria 9, I-10125 Torino, Italy 
b
Dipartimento di Sanità Pubblica-Microbiologia-Virologia, Università degli Studi di Milano, Via 
Pascal 36, 20133 Milano, Italy 
c
 .La Jolla Bioengineering Institute, 505 Coast Boulevard South Suite 406, La Jolla, CA, 92037 USA
 
 
Abstract 
The synthesis and physico-chemical properties of novel compounds obtained by conjugation of  
amodiaquine with moieties containing either furoxan or nitrooxy NO-donor substructures are 
described. The synthesised compounds were tested in vitro against both the chloroquine sensitive , 
D10 and the chloroquine resistant, W-2 strains of Plasmodium falciparum (P. falciparum). Most of 
the compounds showed an antiplasmodial activity comparable to that of the parent drug. By 
comparing the activities of simple related structures devoid of the ability to release NO, it appears 
that the contribution of  NO to the antiplasmodial action in vitro is marginal. All the compounds 
were able to relax rat aorta strips with a NO-dependent mechanism, thus showing their capacity to 
release NO in the vessels. A preliminary in vivo study using Plasmodium berghei ANKA-infected 
mice showed a trend for prolonged survival of mice with cerebral malaria treated with compound 
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40, which is potent and fast amodiaquine-derived NO donor, when compared with amodiaquine 
alone or with compound 31, a milder NO-donor. The two compounds showed in vivo 
antiplasmodial activity similar to that of amodiaquine. 
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1. Introduction 
Malaria is one of the most important causes of parasitic infection and death in the world. A WHO 
report estimates in 189-327 millions the cases of malaria and in about 1 million the associated 
deaths, the major part of them occurring in children living in sub-Saharan Africa [1]. There is an 
increasing need both of new antimalarial drugs and of improvements of those already in use, in 
particular of agents active against the infection due to Plasmodium falciparum, which is the main 
agent of severe malaria.  
Nitric oxide (NO) is a physiological messenger with multiple actions. In the cardiovascular system 
it is involved in maintaining the micro- and macro-vascular homeostasis [2]. In particular, it induces 
vasodilation and inhibits platelet aggregation through a cyclic GMP (cGMP) dependent mechanism 
and it modulates the expression of the cell-adhesion molecules (CAMs) on endothelial cells. In the 
central nervous system, it plays complex roles in learning, memory formation and neurotransmitters 
release, while in the peripheral nervous system behaves as a neurotransmitter at the ends of non-
adrenergic, non-cholinergic nerves controlling a number of gastrointestinal, respiratory and 
genitourinary functions [3]. In the innate immune system NO is one of  the final effector molecules 
against pathogens of different origin. It regulates other immunological functions, as well, including 
T- and B-cell proliferation, leukocytes rolling and cytokines production [4]. Finally, NO seems to 
play an important role in the pathogenesis of P falciparum malaria both as antiplasmodial agent and 
regulator of the immune response to the parasite. This suggested the hypothesis that derivatives of 
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NO could be effective antimalarial agents [5]. Indeed, it was found that some NO-donors display in 
vitro toxic action against P. falciparum [6-8]. 
Severe falciparum malaria, including cerebral malaria (CM), is associated with tissue ischemia 
related to cytoadherence of parasitized erythrocytes to microvascular endothelium. CM has been 
reported to be associated  to low NO bioavailability in the vasculature [9,10]. This is due to both an 
increased scavenging of NO in the blood, caused by the high concentration of free oxyhaemoglobin 
(HbO
2+
) from the haemolysis of parasitized red blood cells and to hypoargininemia. Administration 
of exogenous NO to the murine model of CM induced by P.berghei ANKA (PbA) restored 
signalling in the brain, decreased proinflammatory biomarkers in the blood, and markedly reduced 
vascular leak and petechial hemorrhages in the brain [10a]. Moreover, a significant improvement of 
CM has been observed in patients after infusion of l-arginine demonstrating that the NO pathway 
can be targeted for adjunctive treatment in falciparum malaria [10b]. Amodiaquine (AQ, Chart 1 ) is 
an established antimalarial drug recently reintroduced in the World Health Organisation Model List 
of Essential Medicines [11, 12]. 
As development of our previous work aimed at designing new NO-donor multifunctional drugs 
[13], we now report a study concerning the synthesis, the dissociation constants and the in vitro anti 
P. falciparum activity of new NO-donor amodiaquine derivatives (NO-AQ) containing either 
furoxan (1,2,5-oxadiazole 2-oxide) or nitrooxy (-ONO2) NO-donor substructures. The capacity of 
NO-AQ of relaxing rat aorta strips with a NO-dependent mechanism, and in vivo preliminary data 
which seem to confirm their potential utility in the treatment of CM, are also discussed.  
 
Insert Chart 1 
 
2. Results and discussion 
 
2.1 Chemistry 
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Derivatives 3, 4, 7, 12-15, bearing nitrooxy functionalities and a primary or a secondary amino 
group, used for building the final nitrooxy substituted compounds, were synthesised following the 
pathways described in Scheme 1. Compounds 3 and 4 were synthesised by nitration with fuming 
nitric acid of the related commercially available amino alcohols 1 and 2. For the synthesis of 6-
(ethylamino)hexan-1-ol (6) the commercially available 6-chlorohexanol (5) was treated with  
ethylamine and then with HCl to give 5aHCl. The hydrochloride was converted into the 
corresponding free base by ion-exchange chromatography on cationic resin (Amberlite IRA-400). 
This base was transformed into 7HNO3 by treatment with fuming nitric acid in 34% overall yield. 
For the synthesis of piperidino- and piperazino-based nitrooxy derivatives, the commercially 
available piperidino or piperazino alcohols 8-11 were nitrated following the usual procedure to 
afford compounds 12-15  in 60-67% yields. 
 
Insert Scheme 1 
 
 
The synthesis of 6-(ethylamino)hexane-1,1-diyl dinitrate (26) was achieved through the route 
depicted in Scheme 2. The commercially available hex-5-en-1-ol (16) was converted into the 
corresponding phtalimido derivative 17, by reaction of the intermediate methansulphonate 16a with 
potassium phtalimide. Double bond oxidation with KMnO4 in acetone/water afforded the diol 18, 
which was then transformed into the dioxolane 19 with acetone and catalytic pyridinium p-
toluensulfonate (PPTS). Cleavage of the phtalimide moiety by refluxing with hydrazine hydrate in 
THF afforded the amine 20. The Fukuyama procedure [14] was used in order to obtain the mono-
alkylated amine 23. 2-nitro-benzenesulphonamide derivative 21, resulting from reaction of 20 with 
2-nitrobenzenesulfonyl chloride in the presence of triethylamine, was alkylated with excess ethyl 
iodide in basic medium to afford 22. Treatment of this product with tiophenol and KOH under 
nitrogen atmosphere gave the expected secondary amine 23. The dioxolane ring of this intermediate 
was cleaved by treatment with refluxing 80 % CF3COOH solution and subsequent conversion of the 
obtained aminodiol trifluoroacetate 24 to the corresponding free base by ion-exchange 
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chromatography; 25 was then treated with fuming nitric acid to afford the final double nitrated 
aminodiol 26 as HNO3 salt. 
 
Insert Scheme 2 
 
 
The synthesis of final AQ derivatives 28-31, 32-35 bearing nitrooxy groups (Scheme 3) was carried 
out by nucleophilic displacement of benzylic chlorine atom present on versatile intermediate 27 we 
have previously described [15], by the appropriate nitrooxy substituted primary and secondary 
amines. The reaction, was performed in a 1:1 mixture of DMF and CH3CN, in the presence of 
triethylamine. Compounds 28-30, 32-35 were converted to the corresponding hydrochlorides by 
treatment of their methanolic solution with HCl-saturated Et2O, while compound 31 was kept as the 
free base. 
 
Insert Scheme 3 
 
 
The final AQ derivatives 37, 40 bearing furoxan moieties were synthesised starting from 27 
(Scheme 4). To obtain the phenylfuroxanyl substituted compound 37 the chloromethyl substituted 
intermediate 27 was transformed into hydroxyamodiaquine 36 by treatment with 2-ethylamino 
ethanol in acetonitrile. This last compound was treated with 3-phenyl-4-benzenesulfonyl furoxan 
and 50% (w/w) NaOH, under nitrogen atmosphere in distilled THF/DMF mixture, to give the 
desired product. Owing to extensive decomposition of the reaction mixture, it was impossible to 
obtain 40 in the same way. This product was obtained by reacting 27 with N-ethyl-2-((3-
phenylsulfonyl)furoxan-4-yl)oxy)ethanamine 39 that, in its turn, was obtained by NaOH-mediated 
reaction of 2-(ethylamino)ethanol with bis-benzenesulfonyl furoxan 38. The proposed structure of 
39 was confirmed by its 
13
C-NMR spectrum, which is typical of a 4-alkoxy-3-phenylsulfonyl 
substituted furoxan [16]. 
Insert Scheme 4 
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2.2 Dissociation constants determination 
 
Potentiometric titrations of the final amodiaquine derivatives were performed with a Sirius 
GLpKa automated potentiometric system. The titrations were carried out in water using methanol in 
different ratios as co-solvent; the aqueous pKas were determined by extrapolation to 0% methanol 
according to Yasuda-Shedlovsky procedure (see experimental). The pKa values are listed in Table 1. 
Using AQ as reference compound (pKa1= 8.47, lateral chain nitrogen; pKa2=7.42, 4-aminoquinoline 
centre) [17] it is reasonable to assign in the analogues 28-35, 37, 40, the higher pKa2 values to the 
basic centre of the lateral chains, and the lower pKa1 values to the 4-aminoquinoline moiety. In the 
case of the piperazino substituted compounds 34, 35, pKa3 values could be related with 
aminoquinoline scaffold, while pKa1 and  pKa2 values with the piperazine substructure. From the 
data of the Table 1, it is immediately deducible that at pH (5.2) of parasite food vacuole all the 
products exist in the dicationic form in equilibrium with the monocationic one, while at 
physiological pH (7.4) as complex equilibrium between neutral, monocationic and dicationic 
species. 
 
2.3 Biological activities 
 
2.3.1 In vitro antimalarial activity against (CQS) D10 and (CQR) W-2 strains of P. falciparum 
 
All the final products were screened in vitro against the chloroquine sensitive (CQ-S) D10 and 
the chloroquine resistant (CQ-R) W-2 strains of P. falciparum. The results, expressed as 50% 
inhibitory concentrations (IC50) are shown in Table 2.  All tested compounds including the NO-AQ 
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derivatives retained significant activity against both strains in the low nM range. The most active 
compounds are the piperidine and the piperazine derivatives 32 and 35, which display an 
antiplasmodial potency near to that of the lead. Also the activity of this class against the W-2, CQ-R 
strain is similar to that of AQ, within the limits of the experimental errors, with the only exception 
of the furoxan and piperazine compounds 40 and 34, respectively, which show signs of cross 
resistance with CQ. 
No activity in the nM range was observed for the simple nitric acid esters 3, 7, 12-15, used to 
prepare the nitrooxysubstituted NO-AQ, as well as for the two simple furoxans A, B (Table 2) 
structurally similar to the furoxan moieties present in 37 and 40 respectively. These results indicate 
that the contribution of NO to the antiplasmodial properties of NO-AQ is, if any, secondary to that 
of the lead structure. 
 
2.3.2 Vasodilator activity 
 
All the NO-AQ products described in this work were able to relax rat aorta strips precontracted with 
phenylephrine. The vasodilator potencies, expressed as EC50, are reported in Table 2. Analysis of 
the data indicates that the most potent compounds appear to be the dinitrooxy- and the furoxan-
substituted products 35 and 40, respectively, which display their action in the nM range. The 
remaining products show EC50 values all included in a very narrow range 0.10÷1.2 M. When the 
experiments were repeated in the presence of 1 M ODQ (1H-1,2,4oxadiazolo4,3-aquinoxalin-
1-one), a well known inhibitor of the soluble guanylate cyclase (sGC), a decrease in the potencies 
was observed. These results indicate the ability of these products to release NO in the vessels with 
consequent NO-dependent vasodilation, thus suggesting their potential use as adjunct therapy for  
CM.  
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2.3.3. Ability of compounds 31 and 40 to improve survival of mice from late-stage cerebral 
malaria (CM).  
 
To test this hypothesis, preliminary in vivo experiments were conducted with compounds 31 and 40 
using the murine model of CM caused by P. berghei ANKA (PbA). Infected mice with late stage 
CM (i.e., presenting neurological signs, hypothermia and low motor scores) treated with compound 
40 (1.4mg per mouse) daily for 5 days presented a trend for delayed mortality and increased 
survival as compared to AQ (1mg per mouse) alone. Compound 40 slightly improved the survival 
to 23% and had an efficacy in parasite clearance (76% reduction of parasitaemia in 24 hours) 
similar to that of AQ (8% survival, 72% of parasite clearance in 24 hours) (Figures 1A and 1C). The 
same trend was not observed with compound 31 (1.15mg per mouse), a milder NO donor (Figures 
1B and 1D). Total parasite clearance with both compounds and AQ was achieved after 72 hours and 
three doses of treatment in mice that survived and no recrudescence was observed after a 5-day 
treatment regimen (Figure 1C and 1D). 
 
Conclusions  
 
We have developed a new series of NO-AQ derivatives which are able to retain a high degree of 
activity  in vitro against both CQ-S and CQ-R strains of P. falciparum. At least in vitro, the 
contribution of NO to the antiplasmodial properties of these products seems to be secondary to that 
of the lead. All the compounds are able, in different degree, to dilate pre-contracted rat aorta strips 
with a NO-dependent mechanism, and consequently they could be capable to help restoring the 
vascular homeostasis which is deeply compromised in CM. Indeed, low NO bioavailability plays a 
role in the pathogenesis of murine CM [10], which is associated with cerebral microcirculatory 
dysfunction and vasoconstriction [18]. Treatment with an NO donor, 1-[N-(3-Aminopropyl)-N-(3-
ammoniopropyl)]diazen-1-ium-1,2-diolate (DPTA-NO) largely prevents the neurological syndrome 
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and this is associated with improved cerebral vascular responses [19]. We asked whether a hybrid 
compound endowed with antimalarial and NO activities could improve survival in mice with late 
stage CM, in comparison with its lead compound presenting antimalarial activity only. Our 
preliminary results with compounds 40 and 31 in the murine model of CM by P. berghei  ANKA 
indeed showed a trend for increased survival of the animals treated with compound 40, which is a 
potent and fast NO-donor. It is remarkable that survival rates were increased three-fold, especially 
considering that mice left untreated at late stage of CM die in a few hours, and AQ by itself was 
highly ineffective at this stage. Earlier treatment and shorter intervals for drug administration may 
help to further improve the efficacy. The same trend for increased survival was not observed with 
compound 31, a milder NO-donor. Further in vivo studies are in progress to disclose the interesting 
potentialities of these products, and of other NO-donor antimalarial drugs, in the treatment of CM. 
 
3. Experimental 
 
3.1. Instrumentation and chemicals 
Melting points were determined with a capillary apparatus Büchi B-540 or Büchi B-530 
(uncorrected). Melting point with decomposition were determined after introduction of the sample 
at a temperature 10 °C lower than the melting point. A heating rate of 2 °C min
-1
 was used. 
1
H and 
13
C NMR spectra were obtained on a Bruker Avance 300, at 300 and 75 MHz respectively or 
Bruker AC-200, at 200 and 50 MHz respectively;  in ppm rel. to SiMe4 as the internal standard; 
coupling constants J in Hz. 
13
C NMR spectra were fully decoupled. The following abbreviations are 
used: s: singlet, d: doublet, dd: doublet doublet, t: triplet, qt: quartet, m: multiplet, br: broad, Fx: 
furoxan, Q: quinoline ring, AQ: amodiaquine. Mass spectra were recorded on a Finnigan-Mat TSQ-
700. Flash chromatography (FC) was performed on BDH silica gel (particle size 40-63 μm). When 
not otherwise specified, anhydrous magnesium sulphate (MgSO4) was used as the drying agent of 
organic phases. Analysis (C, H, N) of the target compounds was performed by Service de 
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Microanalyse, Université de Genève, Genève (CH) and REDOX (Monza) and the results were 
within  0.4% of the theoretical. 3-phenyl-4-benzenesulfonyl furoxan [20], 3 [21], 27 [15], 38 [22], 
A, B [23], were synthesised according to reported methods. 
 
3.2. Chemistry 
3.2.1. 6-(ethylamino)hexan-1-ol (6) 
6-chlorohexan-1-ol (5) (3.5 g; 26 mmol) was added to 70 ml of EtNH2 70% solution in water. The 
solution was kept under stirring at room temperature for 48 h. The solution was then evaporated 
under reduced pressure and the residue was taken up with 1N HCl and washed three times with 
CH2Cl2; the aqueous phase was filtered and dried under reduced pressure. The residue was eluted 
through an ion-exchange column over Amberlite IRA-400 resin to afford 1.76 g of the title product 
as a colourless oil (52% free base). 
1
H-NMR (CD3OD): δ, 3.58 – 3.53 (m, 2H, CH2O); 3.02 – 2.89 
(m, 4H, CH2NHCH2); 1.68 – 1.41 (m, 6H, 3 CH2); 1.28 (t, J = 7.2 Hz, 3H, CH3). 
13
C-NMR 
(CD3OD): δ, 61.3; .47.4; 42.8; 32.0; 26.5; 26.2; 25.2; 10.8. MS CI (isobutane) (m/z): 146 [MH
+
]. 
 
3.2.2. N-ethyl-6-(nitrooxy)hexan-1-ammonium nitrate (7) 
To 10 ml of fuming nitric acid at – 15 °C, 0.55g (3.8 mmol) of 6 were added dropwise. The mixture 
was allowed to warm at room temperature and was kept under stirring for 24 h. The solution was 
then evaporated under reduced pressure and the residue was dropped in 100 ml of anhydrous Et2O 
at – 15 °C. After 2 h at 0 °C the solvent was decanted off and the semisolid residue was triturated 
several times with fresh diethyl ether and was used without further purification. The product was 
characterized as free base which was obtained by extraction of a slurry of the semisolid with 
Na2CO3, with EtOAc. The organic phase was then washed with brine, dried over Na2SO4 and the 
solvent was evaporated under reduced pressure. The residue was purified by flash chromatography 
on silica gel eluting with DCM/MeOH 5 % to afford 0.62 g of the desired product as a colorless oil 
(65 %). 
1
H-NMR (DMSO-d6): δ, 4.51 (t, J = 6.1 Hz, 2H, CH2ONO2); .2.55 – 2.43 (m, 4H, 
12 
 
CH2NCH2); 1.70 – 1.61 (m, 2H, CH2); 1.44 – 1.31 (m, 6H, 3CH2); 0.99 (t, J = 7.1 Hz, 3H, CH3). 
13
C-NMR (DMSO-d6): δ, 74.2; 49.2; 43.8; 29.3; 26.7; 26.4; 25.4; 15.1. 
 
3.2.3. General procedure for the synthesis of derivatives 4, 12–15. 
The appropriate alcohol was added dropwise to 15 ml of fuming nitric acid at – 15 °C. The mixture 
was allowed to warm at room temperature and was kept under stirring for 24 h. The solution was 
then evaporated under reduced pressure and the residue was dropped in 100 ml of anhydrous Et2O 
at – 15 °C. After 2 h at 0 °C the solvent was decanted off and the semisolid residue was triturated 
several times with fresh diethyl ether to obtain an off-white solid (60-93% yields). 
 
3.2.3.1. N-ethyl-3-(nitrooxy)propan-1-ammonium nitrate (4). 
1
H-NMR (DMSO-d6): δ, 8.45 (s, 2H, exch. sign.); 4.60 (t, J = 4.5 Hz, 2H, CH2ONO2); 2.99 (m, 2H, 
CH2CH2CH2); 1.17 (t, J = 5.5 Hz, 3H, CH3). 
13
C-NMR (DMSO-d6): δ, 70.8; 43.2; 42.2; 23.2; 11.0. 
 
3.2.3.2. 4-[(nitrooxy)methyl]piperidinium nitrate (12). 
1
H-NMR (DMSO-d6): δ, 8.68 (br s, 1H, NH
+
); 8.34 (br s, 1H, NH
+
); 4.45 (d, J = 6.4 Hz, 2H, 
CH2ONO2); 3.34 – 3.30 (m, 2H, CH2-piperidine); 2.98 – 2.86 (m, 2H, CH2-piperidine); 2.10 – 2.04 
(m, 1H, CH-piperidine); 1.87 – 1.82 (m, 2H, CH2-piperidine); 1.51 – 1.38 (m, 2H, CH2-piperidine). 
13
C-NMR (DMSO-d6): δ, 76.6; 42.8; 31.4; 25.1. Spectral data were consistent with the reported 
ones[22].  
 
3.2.3.3. 4-[2-(nitrooxy)ethyl]piperidinium nitrate (13). 
1
H-NMR (CD3OD): δ, 4.45 (t, J = 6.3 Hz, 2H, CH2ONO2); 3.30 – 3.25 (m, 2H, CH2-piperidine) 
2.91 – 2.83 (m, 2H, CH2-piperidine); 1.88 – 1.83 (m, 2H, CH2-piperidine); 1.64 – 1.58 (m, 3H, 
CH2, CH); 1.37 – 1.30 (m, 2H, CH2-piperidine). 
13
C-NMR (CD3OD): δ, 71.5; 55.2; 53.3; 44.5; 
33.0; 31.3; 29.0. Spectral data were consistent with the reported ones[24]. 
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3.2.3.4. 1-[2-(nitrooxy)ethyl]piperazin-4-ium nitrate (14). 
1
H-NMR (DMSO-d6): δ, 9.09 (br s, 2H, 2NH
+
); 4.87 (t, J = 4.6 Hz, 2H, CH2ONO2); 3.62 (m, 2H, 
CH2-lateral chain); 3.41 – 3.32 (m, 8H, 4CH2-piperazine). 
13
C-NMR (DMSO-d6): δ, 67.3; 52.6; 
48.6; 40.4. Spectral data were consistent with the reported ones [25].  
 
3.2.3.5. 1-[3-(nitrooxy)propyl]piperazin-4-ium nitrate (15). 
1
H-NMR (DMSO-d6): δ, 9.10 (br s, 2H, 2NH
+
); 4.61 (t, J = 6.0 Hz, 2H, CH2ONO2); 4.0 – 3.28 (m, 
10H, 5 CH2); 2.14 – 2.05 (m, 2H, CCH2C-lateral chain). 
13
C-NMR (DMSO-d6): δ, 70.8; 52.7; 48.5; 
40.6; 21.4. Spectral data were consistent with the reported ones [25]. 
 
3.2.4. 2-hex-5-enyl-1H-isoindole-1,3(2H)-dione (17). 
5-hexen-1-ol 16 (10 g, 10 mmol) was converted to the corresponding methanesulfonate according to 
a reported procedure [26]. The crude product was then suspended in CH3CN with potassium 
phtalimide (1.5 eq) and a catalytic amount of potassium iodide. The mixture was refluxed for 72 h, 
then cooled and filtered on a sintered-glass funnel. The filtrate was purified by flash 
chromatography eluting with PE/EtOAc 10% to afford the desired product as a white solid (20 g, 
86%). Spectral data were consistent with the reported ones [27]. 
1
H-NMR (CDCl3): δ, 7.86 - 7.80 
(m, 2H arom); 7.64 - 7.68 (m, 2H arom); 5.85 - 5.71 (m, 1H, CH=); 5,04 - 4.92 (m, 2H, CH2=); 3.69 
(t, 2H, J = 7.2Hz, CH2N); 2.13 - 2.05 (m, 2H, CH2CH); 1.72 - 1.67 (m, 2H, CH2); 1.50 - 1.40 (m, 
2H, CH2). 
13
C-NMR (CDCl3): δ, 168.4; 138.2; 133.8; 132.1; 123.1; 114.9; 37.8; 33.2; 28.0; 26.1; 
21.0. MS CI (isobutane) (m/z): 230 [MH
+
]. M.p. (n-hexane): 52.5 °C. 
 
3.2.5. 2-(5,6-dihydroxyhexyl)-1H-isoindole-1,3(2H)-dione (18). 
To a solution of 5 g of 17 (22 mmol) in 200 ml of acetone cooled in an ice bath, a solution of 
KMnO4 in 200 ml of water was added dropwise. After the addition was over the mixture was 
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allowed to raise to room temperature and kept under stirring for further 3 h; the brownish solid was 
filtered off on a sintered glass funnel and the filtrate was concentrated under reduced pressure. The 
residue was taken up with 100 ml of water and extracted with EtOAc (6 x 50 ml). The organic 
extracts were washed with brine (1 x 100 ml), dried and the solvent was evaporated under reduced 
pressure. The crude product was purified by flash chromatography on silica gel eluting with 
CH2Cl2/CH3OH 5% to afford 3.16 g (56%) of the desired product as white solid. Spectral data were 
consistent with the reported ones [28]. 
1
H-NMR (CD3OD): δ, 7.85 - 7.76 (m, 4Harom); 3.70 - 3.30 
(m, 5H, CH2N, CHOH,CH2OH); 1.74 - 1.27 (m, 6H, CH2CH2CH2). 
13
C-NMR (CD3OD): δ, 169.8; 
135.3; 133.4; 124.0; 73.0; 67.3; 38.8; 33.9; 29.6; 24.0; 23.3. 
MS (CI) (isobutane) (m/z): 264 [MH
+
]. M.p. (iPr2O / iPrOH): 65 °C. 
 
3.2.6. 2-[4-(2,2-dimethyl-1,3-dioxolan-4-yl)butyl]-1H-isoindole-1,3(2H)-dione (19). 
To a solution of 18 (3.16 g;12 mmol) in 200 ml of acetone, pyridinium p-toluenesulfonate (0.3 g; 1 
mmol) was added. The mixture was stirred at room temperature for 18 h, then evaporated under 
reduced pressure and purified by flash chromatography on silica gel to afford 3.03 g (80 %) of title 
product as a white solid. Spectral data were consistent with the reported ones [28]. 
1
H-NMR 
(CDCl3): δ, 7.86 - 7.80 (m, 2H arom); 7.74 - 7.68 (m, 2H arom); 4.11 - 4.00 (m, 2H, 2CHO); 3.70 
(t, J = 7.2 Hz, 2H, CH2N); 3.54 – 3.44 (m, 1H, CHO); 1.77 – 1.46 (m, 6H, 3CH2); 1.40 (s, 3H, 
CH3); 1.34 (s, 3H, CH3). 
13
C-NMR (CDCl3): δ, 168.4; 165.7; 133.9; 132.1; 123.2; 108.72; 75.8; 
71.9; 69.4; 37.8; 33.1; 28.6; 26.9; 25.7; 23.1. MS CI (isobutane) (m/z): 304 [MH
+
]. M.p. (n-
hexane): 121 °C. 
 
3.2.7. 4-(2,2-dimethyl-1,3-dioxolan-4-yl)butan-1-amine (20). 
To a stirred solution of 19 (3 g;10 mmol) in 100 ml of distilled THF, hydrazine monohydrate (3.9 
ml; 8 eq.) was added and the mixture was stirred under reflux for 24 h. After cooling the mixture 
was filtered on a sintered-glass funnel and the filtrate was evaporated under reduced pressure. The 
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residue was purified by flash chromatography on silica gel eluting with DCM/MeOH 5%, 
DCM/MeOH 10% NH3 soln 1% affording the desired product as a colourless oil (0.9g 52%). 
Spectral data were consistent with the reported ones [29]. 
1
H-NMR (CDCl3): δ, 4.13 - 4.01 (m, 2H, 
CH2O); 3.54 - 3.47 (m, 1H, CH); 2,7 (t, 2H, J = 6.9 Hz,CH2N); 1.95 (s, 3H, CH2, CH); 1.40 (s, 3H, 
CH3); 1.35 (s, 3H, CH3). 
13
C-NMR (CDCl3): δ, 108.6; 77.2; 75.9; 69.4; 41.8; 33.3; 26.9; 25.7; 23.2. 
MS CI (isobutane) (m/z): 174 [MH
+
]. 
 
3.2.8. N-[4-(2,2-dimethyl-1,3-dioxolan-4-yl)butyl]-2-nitrobenzenesulfonamide (21). 
To a solution of 0.9 g (5 mmol) of 20 and Et3N (1.1 eq) in 20 ml of DCM cooled in an ice bath, 2-
nitrobenzensulfonilchloride (1 eq) was added portionwise. The mixture was stirred at RT for 30 
min, taken up with DCM and washed with 20 ml of 1N HCl; the aqueous phase was extracted with 
DCM (2 x 10 ml) and the organic phase was then washed with water and brine, dried over Na2SO4, 
filtered and evaporated under reduced pressure. The residue was purified by flash chromatography 
on silica gel, eluting with PE/EtOAc 30% to afford the desire product as a colourless oil (1.55 g, 
83%). 
1
H-NMR (CDCl3): δ, 8.13 – 8.10 (m, 1H arom); 7.86 – 7.77 (m, 3H arom); 5.76 - 5.73 (m, 
1H, CH); 4.14 - 3.98 (m, 2H, CH2O); 3.38 – 3.44 (m, 1H, NH); 3.13 (qt, 2H, J = 6.3 Hz, CH2N); 
1.60 - 1.36 (m, 6H, CH2CH2CH2); 1.32 (s, 3H, CH3); 1.26 (s, 3H, CH3). 
13
C-NMR (CDCl3): δ, 
148.2; 135.6; 134.2; 133.6; 133.2; 131.1; 125.5; 108.8; 76.0; 69.5; 43.9; 33.2; 29.8; 27.2; 26.0; 
25.5; 23.0; 14.5. MS CI (isobutane) (m/z): 359 [MH
+
]. 
 
3.2.9. N-[4-(2,2-dimethyl-1,3-dioxolan-4-yl)butyl]-N-ethyl-2-nitrobenzenesulfonamide (22). 
To a stirred solution of 21 (1.55 g; 4.3 mmol) in 50 ml of DMF, K2CO3 (10 eq) and EtI (1.5 eq) 
were added. The solution was stirred at 60 °C for 10 hrs, taken up with 100 ml of Et2O and washed 
with water (3 x 50 ml) and brine; the organic phase was dried over Na2SO4, filtered and dried under 
reduced pressure. The residue was purified by flash chromatography on silica gel eluting with 
PE/EtOAc 30%, to afford the desired product as a pale yellow oil (1.63 g 98%). 
1
H-NMR (CDCl3): 
16 
 
δ, 8.02 – 7.99 (m, 1H arom); 7.70 - 7.67 (m, 2H arom); 7.65 – 7.60 (m, 1H, arom); 4.07 – 3.99 (m, 
2H, CH2O); 3.50 – 3.46 (m, 1H, CH); 3.40 – 3.28 (m, 4H, NCH2CH3, NCH2); 1.66 - 1.29 (m, 12H, 
3 CH2, CH3CCH3); 1.12 (t, J = 7.2 Hz, 3H, CH3CH2). 
13
C-NMR (CDCl3): δ, 133.8, 133.4, 
130.6,127.0, 75.8, 69.3, 46.7, 42.0, 36.5, 33.0, 31.4, 28.3, 26.9, 25.7, 22.8, 13.7. MS CI (isobutane) 
(m/z): 387 [MH
+
]. 
 
3.2.10. N-[4-(2,2-dimethyl-1,3-dioxolan-4-yl)butyl]-N-ethylamine (23). 
A solution of 1.08 ml (2.5 eq) of thiophenol in 15 ml of CH3CN kept under N2 was cooled in an ice 
bath. To this solution 0.60 g of KOH (2.5 eq) dissolved in 2ml of water were added dropwise. After 
10 min 1.63 g of 22 (0.004 mol) dissolved in 10 ml of CH3CN were added dropwise over a period 
of 20 min. The mixture was stirred at 50 °C for 4 h, then it was filtered and the filtrate was 
evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel, 
eluting with DCM, DCM/MeOH 5%, DCM/MeOH 10% NH3 1% to afford the title product as a 
colourless oil (0.65 g 77%). 
1
H-NMR (CDCl3): δ, 4.10 - 4.01 (m, 2H, CH2O); 3.50 (t, 1H, J = 7.09 
Hz, CH); 2.70 - 2.60 (m, 4H, CH2NCH2); 1.66 - 1.43 (m, 6H, CH2CH2CH2); 1.41 (s, 3H, CH3); 1.37 
(s, 3H, CH3); 1.12 (t, 3H, J = 7.2 Hz, CH3CH2). 
13
C-NMR (CDCl3): δ, 108.7; 69.5; 49.5; 44.1; 33.5; 
29.9; 27.0; 25.7; 23.6; 15.1. MS CI (isobutane) (m/z): 202 [MH
+
]. 
 
3.2.11. 6-(ethylamino)hexane-1,2-diol (25). 
ofCompound 23 (0.64 g; 3.2 mmol) was dissolved in 20 ml of 80% TFA in water. The mixture was 
refluxed for 24 hrs, then it was evaporated under reduced pressure. The residue was taken up with 
20 ml of water and activated carbon was added; the suspension was heated to boiling and filtered 
through a bed of celite. The filtrate was evaporated under reduced pressure and the residue was 
eluted through an ion-exchange column over Amberlite IRA-400 resin to afford 0.42 g of the title 
product as a colourless oil (82% free base). 
1
H-NMR (CD3OD): δ, 3.61 - 3.59 (m, 1H, CHOH); 3.47 
- 3.45 (m, 2H, CH2OH); 3.10 - 2.97 (m, 4H, CH2NHCH2); 1.73 - 1.40 (m, 6H, CH2CH2CH2); 1.31 
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(t, 3H, J = 7.4 Hz, CH3). 
13
C-NMR (CD3OD): δ, 72.8; 67.2; 48.4; 44.0; 33.7; 27.3; 23.6; 11.6. MS 
CI (isobutane) (m/z): 162 [MH
+
]. 
 
3.2.12. N-ethyl-5,6-bis(nitrooxy)hexan-1-ammonium nitrate (26). 
To 20 ml of fuming nitric acid cooled at –15 °C, 25 (1.5 g; 9.3 mmol) was added dropwise over a 
period of 10 min The mixture was then allowed to warm to room temperature and was kept under 
stirring for 40 h. After that period the solvent was distilled under reduced pressure and the residue 
was dropped and triturated in 150 ml of dry diethyl ether at -15 °C. The white solid thus obtained 
was collected through filtration and washed thoroughly with dry diethyl ether to afford 1.97 g of the 
title compounds (67% as nitric acid salt). 
1
H-NMR (DMSO-d6): δ, 8.21 (br s, 2H NH2
+
) 5.46 - 5.39 
(m, 1H, CHONO2); 4.97 - 4.92 (dd, J1 = 2.4 Hz, J2 = 12.9 Hz, 1H, CH’H’’ONO2); 4.74 - 4.68 (dd, 
J1 = 6.2 Hz, J2 = 12.8 Hz, 1H, CH’H’’ONO2); 2.99 - 2.85 (m, 4H, CH2NH2
+
CH2) 1.78 - 1.70 (m, 
2H, CH2); 1.63 - 1.37 (m, 6H, 2CH2) 1.16 (t, 3H, J = 7.2 Hz, CH3). 
13
C-NMR (DMSO-d6): δ, 80.0; 
71.8; 45.8; 41.8; 27.6; 25.1; 21.3; 10.9. M.p.: 64 - 65 °C. Anal. Calc. for: C8H17N3O6∙HNO3∙0.5H2O 
C% 29.72, H% 5.92, N% 17.33; Found 29.61, H% 5.65, N% 17.53. 
 
3.2.13. General procedure for the synthesis of the derivatives 28-35. 
The appropriate nitric ester and 27 (1 eq.) were suspended in a mixture of CH3CN/DMF 1/1. To the 
suspension, cooled at 0 °C, 3.5 eq. of Et3N were added dropwise. The mixture was kept under 
stirring at room temperature for 6 h. After that period the solvent was distilled under reduced 
pressure and the residue was taken up with water and extracted with EtOAc. The organic phase was 
washed with brine, dried over Na2SO4, filtered and evaporated under reduced pressure. The residue 
was purified by flash chromatography on silica gel eluting with mixture of DCM/MeOH to afford 
the desired products as yellow solids in 35 – 56% yields. 
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3.2.13.1. 7-chloro-4-{[4-hydroxy-3-({[3-
(nitrooxy)propyl]ammonio}methyl)phenyl]amino}quinolinium dihydrchloride (28). 
The free base was taken up with MeOH and HCl saturated Et2O was added at 0 °C; the solution was 
kept under stirring at room temperature for two hours, then the solvent was evaporated under 
reduced pressure and the solid was freeze dried to give the product as the hydrochloride. 
1
H-NMR 
(DMSO-d6): δ, 11.20 (br s, 1H, exch. signal); 10.79 (br s, 1H, exch. signal); 9.50 (br s, 2H, exch. 
signal) 8.95 (d, J = 9.0 Hz, 1H arom.); 8.46 (d, J = 7.0 Hz, 1H arom.); 8.19 (d, J = 1.9 Hz, 1H 
arom.); 7.82 (dd, J1 = 9.0 Hz, J2 = 1.9 Hz, 1H arom.); 7.60 (d, J = 2.3 Hz, 1H arom.); 7.34 (d, J1 = 
8.6 Hz, J2 = 2.3 Hz, 1H arom.); 7.19 (d, J = 8.6 Hz, 1H arom.); 6.86 (dd, J = 7.0 Hz, 1H arom.); 
4.66 (t, J = 6.0 Hz, 2H, CH2ONO2); 4.13 (s, 2H, CH2Ph); 3.06 (m, 2H, CH2N); 2.17 (m, 2H, 
CCH2C). 
13
C-NMR (DMSO-d6): δ, 155.4; 155.3; 154.9; 142.9; 138.8; 138.2; 128.7; 127.8; 127.2; 
125.9; 119.2; 119.0; 116.4; 115.5; 100.2; 70.7; 44.6; 43.2; 22.8. M. p.: 177 - 179 °C (dec.). Anal. 
Calc. for: C19H19ClN4O4∙2HCl∙1.7H2O C% 45.07, H% 4.86, N% 11.06; Found 45.16, H% 4.49, N% 
10.69. 
 
3.2.13.2. 7-chloro-4-{[3-({ethyl[3-(nitrooxy)propyl]ammonio}methyl)-4-
hydroxyphenyl]amino}quinolinium dihydrochloride (29). 
The free base was taken up with MeOH and HCl saturated Et2O was added at 0 °C; the solution was 
kept under stirring at room temperature for two hours, then the solvent was evaporated under 
reduced pressure and the solid was freeze dried to give the product as the hydrochloride. 
1
H-NMR 
(free base) (CDCl3): δ, 8.42 (d, J = 5.6 Hz, 1H arom.); 7.97 – 7.93 (m, 2H arom.); 7.41 (dd, J1 = 9.0 
Hz, J2 = 2.5 Hz, 1H arom.); 7.14 (dd, J1 = 8.2 Hz, J2 = 2.5 Hz, 1H arom.); 6.96 (d, J = 2.5 Hz, 1H 
arom.); 6.87 (d, J = 8.2 Hz, 1H arom.); 6.63 (d, J = 5.6 Hz, 1H arom.); 4.49 (t, J = 6.2 Hz, 2H, 
CH2ONO2); 3.77 (s, 2H, CH2Ph); 2.67 (m, 4H, CH2NCH2); 1.99 (m, 2H, CCH2C); 1.13 (t, J = 
7.2Hz, 3H, CH3). 
13
C-NMR (free base) (CDCl3): δ, 156.1; 150.7; 149.7; 148.3; 135.5; 129.9; 127.7; 
125.8; 125.7; 125.2; 125.1; 117.1; 101.1; 70.8; 57.2; 49.1; 47.1; 24.0; 10.9. MS CI (free base) 
19 
 
(isobutane) (m/z): 431 / 433 [MH
+
]. M. p.: 182 - 183 °C (dec.). Anal. Calc. for: 
C21H23ClN4O4∙2HCl∙1.5H2O C% 47.51, H% 5.31, N% 10.55; Found 47.62, H% 5.02, N% 10.27. 
 
3.2.13.3. 7-chloro-4-{[3-({ethyl[6-(nitrooxy)hexyl]ammonio}methyl)-4-
hydroxyphenyl]amino}quinolinium dihydrochloride (30). 
The free base was taken up with MeOH and HCl saturated Et2O was added at 0 °C; the solution was 
kept under stirring at room temperature for two hours, then the solvent was evaporated under 
reduced pressure and the solid was freeze dried to give the product as the hydrochloride. 
1
H-NMR 
(CD3OD): δ, 8.65 (d, J = 9.1 Hz, 1H arom.); 8.39 (d, J = 7.1 Hz, 1H arom.); 7.76 (dd, J1 = 9.1 Hz, 
J2 = 1.9 Hz, 1H arom.); 7.61 (d, J = 2.5 Hz, 1H arom.); 7.45 (dd, J1 = 8.7, Hz, J2 = 2.5 Hz, 1H 
arom.); 7.15 (d, J = 8.7 Hz, 1H arom.); 6.86 (d, J = 7.1 Hz, 1H arom.); 4.49 (t, J = 6.5 Hz, 2H, 
CH2ONO2); 4.23 (s, 2H, CH2Ph); 3.30 – 3.20 (m, 4H, CH2NCH2); 1.83 (m, 2H, CH2); 1.74 (m, 2H, 
CH2) 1.42 (m, 7H, 2CH2, CH3). 
13
C-NMR (CD3OD): δ, 157.8; 157.5; 144.2; 141.4; 140.5; 131.4; 
130.5; 129.9; 129.1; 126.5; 120.4; 119.3; 118.0; 117.2; 101.7; 74.5; 53.7; 52.6; 49.8; 27.6; 27.3; 
26.3; 24.6; 9.2. M. p.: 191 - 193 °C (dec.). Anal. Calc. for: C24H29ClN4O4∙2HCl∙H2O C% 51.31, 
H% 5.77, N% 9.90; Found 51.12, H% 5.90, N% 9.94. 
 
3.2.13.4. 6-[{5-[(7-chloroquinolin-4-yl)amino]-2-hydroxybenzyl}(ethyl)amino]hexan-1,2-diyl 
dinitrate (31). 
1
H-NMR (CD3OD): δ, 8.32 - 8.24 (m, 2H arom.); 7.85 (s, 1H arom.); 7.49 - 7.46 (m, 1H arom.); 
7.16 (d, J = 4.5 Hz, 1H arom); 7.08 (s, 1H arom.); 6.88 - 6.84 (m, 1H arom.); 6.66 - 6.64 (m, 1H 
arom.); 5.43 - 5.39 (m, 1H, CHONO2); 4.96 - 4.88 (m, 1H, CH2ONO2); 4.63 - 4.56 (m, 1H, 
CH2ONO2); 3.84 (s, 2H, PhCH2N); 2.73 - 2.61 (m, 4H, CH2NCH2); 1.82 - 1.49 (m, 6H, 
CH2CH2CH2); 1.19 - 1.15 (m, 3H, CH3). 
13
C-NMR (DMSO-d6): δ, 154.8; 151.8; 149.44; 149.38; 
133.7; 130.4; 127.5; 125.4; 124.6; 124.5; 124.2; 124.0; 117.6; 116.0; 100.4; 80.2; 71.8; 55.0; 51.9; 
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46.4; 28.0; 25.5; 22.1; 10.8. M. p.: 120 -122 °C (dec.). Anal. Calc. for C24H28ClN5O7 C% 53.09, 
H% 5.38, N% 12.90; Found C% 52.79, H% 5.12, N% 12.61. 
 
3.2.13.5. 7-chloro-4-{[4-hydroxy-3-({4-[(nitrooxy)methyl]piperidinium-1-
yl}methyl)phenyl]amino}quinolinium dihydrochloride (32). 
The free base was taken up with MeOH and HCl saturated Et2O was added at 0 °C; the solution was 
kept under stirring at room temperature for two hours, then the solvent was evaporated under 
reduced pressure and the solid was freeze dried to give the product as the hydrochloride. 
1
H-NMR 
(free base) (DMSO-d6): δ, 8.90 (s, 1H arom.); 8.43 - 8.36 (m, 2H arom.); 7.85 (d, J = 1.8 Hz, 1H 
arom.); 7.52 (dd, J1 = 7.2, Hz, J2 = 1.8 Hz, 1H arom.); 7.10 – 7.08 (m, 2H arom.); 6.82 (d, J = 9.2 
Hz, 1H arom.); 6.57 (d, J = 5.4 Hz, 1H arom.); 4.42 (d, J = 6.3 Hz, 2H, CH2ONO2); 3.64 (s, 2H, 
CH2Ph); 2.91 – 2.51 (m, 2H, CH2-piperidine); 2.11 – 2.04 (m, 2H, CH2-piperidine); 1.79 – 1.70 (m, 
3H, CH-piperidine, CH2-piperidine) 1.32 – 1.28 (m, 2H, CH2-piperidine). 
13
C-NMR (free base) 
(DMSO-d6): δ, 154.0; 151.8; 149.4; 149.0; 133.7; 131.2; 129.4; 127.8; 127.5; 124.7; 124.1; 117.7; 
116.8; 116.4; 100.8; 77.2; 65.3; 59.3; 54.0; 34.7; 28.2. M. p.: 170 - 172 °C (dec.). Anal. Calc. for: 
C22H25ClN4O4∙2HCl∙2H2O C% 47.88, H% 5.30 N% 10.15; Found 47.60, H% 4.87, N% 10.07. 
 
3.2.13.6. 7-chloro-4-{[4-hydroxy-3-({4-[2-(nitrooxy)ethyl]piperidinium-1-
yl}methyl)phenyl]amino}quinolinium dihydrochloride (33). 
The free base was taken up with MeOH and HCl saturated Et2O was added at 0 °C; the solution was 
kept under stirring at room temperature for two hours, then the solvent was evaporated under 
reduced pressure and the solid was freeze dried to give the product as the hydrochloride. 
1
H-NMR 
(free base) (CD3OD + CDCl3): δ, 8.28 (d, J = 5.6 Hz, 1H arom.); 8.21 (d, J = 9.0 Hz, 1H arom.); 
7.83 (d, J = 2.0 Hz, 1H arom.); 7.44 (dd, J1 = 6.9, Hz, J2 = 2.1 Hz, 1H arom.); 7.13 (dd, J1 = 6.0, 
Hz, J2 = 2.5 Hz, 1H arom.); 7.02 (d, J = 2.4 Hz, 1H arom.); 6.84 (d, J = 8.5 Hz, 1H arom.); 6.62 (d, 
J = 5.6 Hz, 1H arom.) 4.54 (t, J = 6.5 Hz, 2H, CH2ONO2); 3.73 (s, 2H, CH2Ph); 3.07 – 3.03 (m, 2H, 
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CH2-piperidine) 2.21 – 2.14 (m, 2H, CH2-piperidine); 1.85 – 1.81 (m, 2H, CH2-piperidine); 1.74 – 
1.68 (m, 2H, CH2-lateral chain); 1.63 – 1.55 (m, 1H, CH-piperidine); 1.46 – 1.33 (m, 2H, CH2-
piperidine). 
13
C-NMR (free base) (CD3OD + CDCl3): δ, 157.2; 156.3; 143.1; 141.1; 140.8; 139.7; 
131.0; 129.3; 128.8; 125.8; 119.8; 117.5; 117.4; 116.5; 101.2; 71.1; 57.9; 55.3; 53.0; 49.7; 32.9; 
31.2; 29.5. MS CI (free base) (isobutane) (m/z): 457 / 459 [MH
+
]. M. p.: 163 - 164 °C (dec.). Anal. 
Calc. for: C23H25ClN4O4∙2HCl C% 52.14, H% 5.14 N% 10.57; Found 51.79, H% 5.34, N% 10.17. 
 
3.2.13.7. 7-chloro-4-{[4-hydroxy-3-({4-[2-(nitrooxy)ethyl]piperazinediium-1-
yl}methyl)phenyl]amino}quinolinium trihydrochloride (34). 
The free base was taken up with MeOH and HCl saturated Et2O was added at 0 °C; the solution was 
kept under stirring at room temperature for two hours, then the solvent was evaporated under 
reduced pressure and the solid was freeze dried to give the product as the hydrochloride. 
1
H-NMR 
(free base) (CD3OD): δ, 8.30 - 8.23 (m, 2H arom.); 7.82 (d, J = 2.1 Hz, 1H arom.); 7.50 (dd, J1 = 
6.9 Hz, J2 = 2.1 Hz, 1H arom.); 7.15 – 6.90 (m, 2H arom.); 6.84 (d, J = 8.5, Hz, 1H arom.); 6.62 (d, 
J = 5.6 Hz, 1H arom.); 4.63 (t, J = 6.5 Hz, 2H, CH2ONO2); 3.74 (s, 2H, CH2Ph); 2.76 (t, J = 5.4 Hz, 
2H, CH2CH2ONO2) 2.57 (br s 8H, 4CH2-piperazine). 
13
C-NMR (free base) (CD3OD): δ, 156.7; 
152.6; 152.2; 149.9; 136.7; 132.1; 127.6; 127.5; 126.9; 126.5; 124.6; 124.1; 119.0; 117.6; 101.8; 
71.4; 60.9; 59.8; 55.9; 54.2; 53.8; 53.3. MS CI (free base) (isobutane) (m/z): 458 [MH
+
]. M. p.: 153 
- 154 °C (dec.). Anal. Calc. for: C22H24ClN5O4∙3HCl∙2.5H2O C% 43.15, H% 5.27 N% 11.44; Found 
42.87, H% 4.93, N% 11.20. 
 
3.2.13.8. 7-chloro-4-{[4-hydroxy-3-({4-[3-(nitrooxy)propyl]piperazinediium-1-
yl}methyl)phenyl]amino}quinolinium trihydrochloride (35). 
The free base was taken up with MeOH and HCl saturated Et2O was added at 0 °C; the solution was 
kept under stirring at room temperature for two hours, then the solvent was evaporated under 
reduced pressure and the solid was freeze dried to give the product as the hydrochloride. 
1
H-NMR 
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(free base) (DMSO-d6): δ, 8.91 (br s, exch. sign. 1H) 8.43 - 8.36 (m, 2H arom.); 7.85 (s, 1H arom.); 
7.54 – 7.51 (m, 1H arom.); 7.11 – 7.09 (m, 2H arom.); 6.84 (d, J = 8.9, Hz, 1H arom.); 6.60 – 6.59 
(m, 1H arom.); 4.55 (t, J = 6.2 Hz, 2H, CH2ONO2); 3.64 (s, 2H, CH2Ph); 2.51 – 2.38 (m, 10H, 
5CH2) 1.85 – 1.81 (m 2H, CH2). 
13
C-NMR (free base) (DMSO-d6): δ, 155.7; 154.8; 153.3; 150.9; 
135.4; 132.0; 129.0; 127.9; 127.3; 126.1; 125.8; 124.9; 119.2; 117.5; 102.0; 73.9; 59.8; 56.8; 55.2; 
53.8; 48.3; 25.1; 14.9. M. p.: 167 - 168 °C (dec.). Anal. Calc. for: C22H24ClN5O4∙3HCl∙2.5H2O C% 
44.10, H% 5.47 N% 11.18; Found 43.81, H% 4.99, N% 10.88. 
 
3.2.14. 4-[(7-Chloroquinolin-4-yl)amino]-2-[ethyl-(2-hydroxyethyl)amino]methylphenol 
dihydrochloride (36) 
To a stirred solution of 2-(ethylamino)ethanol (0.82 mL; 8.43 mmol) in CH3CN (20 mL), kept 
under nitrogen, 27 (1 g; 2.81 mmol) was added. The yellow suspension was stirred for 18 h. The 
solvent was evaporated and the yellow residue was treated with water (15 mL) and stirred for 15 
min. The solid was collected on a buchner funnel and washed with water (50 mL). After drying 
over P2O5 the product was purified by flash chromatography eluting with CH2Cl2/MeOH 20% to 
give 36 (0.72 g; 69%) as yellow solid. The product was converted into the corresponding 
hydrochloride by treatment with HCl saturated MeOH and recrystallised from dry MeOH/Et2O to 
obtain an analytical sample. Mp: 228-229.5 °C (dec.) (230 °C dec. [30]).
 1
H NMR (DMSO-
d6+D2O): , 8.33 (d, 1H, J = 9.1 Hz, AQ-H5); 8.21 (d, 1H, J = 7.1 Hz, AQ-H2); 7.82 (d, 1H, J = 2 
Hz, AQ-H8); 7.65 (dd, 1H, J = 2, 9.1 Hz, AQ-H6); 7.38 (d, 1H, J = 2.5 Hz, AQ-H3’); 7.34 (dd, 1H, J 
= 2.5, 8.6 Hz AQ-H5’); 7.06 (d, 1H, J = 8.6 Hz, AQ-H6’); 6.72 (d, 1H, J = 7.1 Hz, AQ-H3); 4.32 (s, 
2H, CH2Ph); 3.79 (t, 2H, J = 5.1 Hz, CH2O); 3.2 (m, 4H, 2(CH2N)); 1.26 (t, 3H, J = 7.2 Hz, CH3). 
13
C NMR (DMSO-d6+D2O): , 154.0 (two overlapping peaks); 141.2; 138.1; 136.9; 128.1; 127.5; 
126.9; 126.5; 123.3; 117.6; 116.2; 115.5; 113.9; 98.7; 53.6; 52.3; 50.6; 47.0; 6.9. MS (free base) 
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(EI) m/z : 371 (52), 340 (35), 283 (100). Anal. Calc. For C20H22ClN3O2 · 2 HCl · 0.1 H2O C% 
53.78, H% 5.46, N% 9.40; found C% 53.58, H% 5.39, N% 9.33. 
 
3.2.15.  4-[(7-Chloroquinolin-4-yl)amino]-2-[(ethyl-[2-(3-phenylfuroxan-4-
yl)oxy]ethyl}amino)methyl]phenol dihydrochloride (37).  
To a suspension of 36 (1.3 g; 2.92 mmol) in distilled THF/DMF 14/1 (27.5 mL), stirred under 
nitrogen at RT, 50% NaOH aqueous solution (14.6 mmol) was added dropwise followed by a 
solution of 3-phenyl-4-benzenesulfonyl furoxan (1.24 g; 4.1 mmol) in distilled THF. The reaction 
mixture was stirred for 5 h, then the mixture was concentrated under reduced pressure to leave a 
brown oil. This residue was taken up with water (20 mL) and extracted with EtOAc (4 x 30 mL). 
The organic phase was washed with brine (40 mL), dried and evaporated under reduced pressure to 
afford the crude product as brown solid. The solid was purified by flash chromatography eluting 
with CH2Cl2/MeOH 3%. The fractions containing the desired product were collected in tubes filled 
with 0.2 mL of HCl saturated MeOH to readily convert the product into the corresponding 
dihydrochloride. After evaporation under reduced pressure 37 was obtained in 50% yield as bright-
yellow solid. The product was recrystallised from MeOH/Et2O. Mp: 229-231 °C (dec.) 
1
H NMR 
(DMSO-d6): , 11.24 (s, 1H, exch. signal); 11.15 (br s, 1H, exch. signal); 10.98 (br s, 1H, exch. 
signal); 8.94 (d, 1H, J = 8.8 Hz, AQ-H5); 8.4 (d, 1H, J = 6.5 Hz, AQ-H2); 8.18 (s, 1H, AQ-H8); 8.02 
(d, 2H, J = 6.8 Hz, FxPh-Ho); 7.81 (d, 1H, J = 8.8 Hz, AQ-H6); 7.71 (s, 1H, AQ-H3’); 7.52 (m, 3H, 
FxPh-Hm; FxPhHp ); 7.38 (d, 1H, J = 8.4 Hz, AQ-H5’); 7.22 (d, 1H, J = 8.4 Hz, AQ-H6’); 6.89 (d, 
1H, J = 6.5 Hz, AQ-H3); 4.97 (br m, 2H, CH2O); 4.26 (s, 2H, PhCH2N); 3.74 (br m, 2H, CH2N); 
3.29 (br m, 2H, CH3CH2N ); 1.36 (br m, 3H, CH3). 
13
C NMR (DMSO-d6): , 161.6; 155.9; 154.6; 
142.8; 138.7; 138.1; 130.5; 130.1; 128.7; 128.4; 127.8; 127.0; 126.3; 126.2; 121.5; 118.9; 117.0; 
116.7; 115.5; 107.6; 100.4; 65.2; 50.2; 49.6; 47.9; 8.5. Anal. Calc. For C28H26ClN5O4 · 2 HCl  C% 
55.59, H% 4.66, N% 11.58; found C% 55.29, H% 4.64, N% 11.44. 
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3.2.16. 2-{[(3-Phenylsulfonylfuroxan-4-yl)oxy]ethyl}ethylamine hydrochloride (39) 
To a stirred solution of 3,4-bis(phenylsulfonyl)furoxan (38) (1 g; 2.72 mmol) in dist. THF (14 
mL) kept under nitrogen, 2-(ethylamino)ethanol (0.54 mL; 5.52 mmol) was added. The obtained 
mixture was cooled to 15 °C and 50% NaOH  aqueous solution (0.64 g; 8.16 mmol) was added 
dropwise. The reaction mixture was stirred for further 40 min and the solvent evaporated under 
reduced pressure to give a yellow solid. The solid was taken up with water (30 mL) and extracted 
with CH2Cl2 (4 x 30 mL), dried (Na2SO4) and evaporated to give the crude product as an oil. The 
product was purified by FC eluting with CH2Cl2/MeOH 5% to obtain the title product (0.4 g; 48%) 
as colorless oil. The product was either used immediately in the next step or stored at –21 °C 
overnight. An analytical sample was obtained as the hydrochloride by treatment with HCl saturated 
MeOH, precipitation with dry Et2O and recrystallisation from dry MeOH/Et2O. Mp: 136.8-138. 
1
H 
NMR (DMSO-d6): , 9.49 (s, 2H, exch. signal); 8.08 (d, 2H, J = 7.5 Hz, Ph-Ho); 7.91 (t, 1H, J = 7.5 
Hz, Ph-Hp); 7.76 (t, 2H, J = 7.7 Hz, Ph-Hm); 4.78 (t, 2H, J = 4.9 Hz, CH2O); 3.35 (m, 2H, CH2N); 
3.08 (q, 2H, J= 7.2 Hz, NCH2CH3); 1.27 (t, 3H, J= 7.2, CH3). 
13
C NMR (DMSO-d6): , 158.5; 
136.8; 136.1; 129.9; 128.5; 110.8; 67.0; 44.2; 42.3; 11.0. Anal. Calc. For C12H15N3O5S · HCl C% 
41.21, H% 4.61, N% 12.01; found C% 41.51, H% 4.81, N% 11.88. 
 
3.2.17. 4-[(7-Chloroquinolin-4-yl)amino]- 2-{[([2-(3-phenylsulfonylfuroxan-4-
yl)oxy]ethyl}ethyl)amino]methyl}phenol dihydrochloride (40) 
To a suspension of 27 (0.9 g; 2.53 mmol) in iPrOH/DMF 10/1 (16.5 mL), stirred under nitrogen 
at RT, triethylamine (10.1 mmol) was added. After 15 min of stirring a solution of 39 (0.7g; 3.54 
mmol) in iPrOH/DMF 10/1 (10 mL) was added dropwise at RT. The reaction mixture was stirred 
for 24 h, the solvent evaporated under reduced pressure to leave an oily residue which was taken up 
with water (20 mL) and extracted with EtOAc (4 x 30 mL). The organic phase was washed with 
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brine (40 mL), dried and evaporated under reduced pressure to give the crude product as light-
brown oil. The product was purified by flash chromatography eluting with CH2Cl2/MeOH 3%. The 
fractions containing the desired product were collected in tubes filled with 0.2 mL of HCl saturated 
MeOH to readily convert the product into the corresponding dihydrochloride. After evaporation 
under reduced pressure 40 was obtained in 40% yield as white solid. The product was recrystallised 
from MeOH. Mp: 214-215 °C (dec.) 
1
H NMR (CD3OD+D2O): ,  8.54 (d, 1H, J = 9.1 Hz, AQ-H5); 
8.3 (d, 1H, J = 7.1 Hz, AQ-H2); 7.98 (d, 2H, J = 7.4 Hz, FxPh-Ho); 7.94 (d, 1H, J = 2 Hz, AQ-H8); 
7.81-7.74 (m, 2H, AQ-H6, FxPh-Hp); 7.69-7.62 (m, 3H, AQ-H3’, FxPh-Hm); 7.48-7.45 (m, 1H, AQ-
H5’); 7.17 (d, 1H, J = 8.7 Hz, AQ-H6’); 6.83 (d, 1H, J = 7.1 Hz, AQ-H3); 4.95 (br m, 2H, CH2O); 
4.64 (s, 2H, PhCH2N); 3.83 (br m, 2H, OCH2CH2N); 3.49 (q, 2H, J = 7.2 Hz, CH3CH2N); 1.38 (t, 
3H, J = 7.2 Hz CH3). 
13
C NMR (CD3OD+D2O): , 159.6; 157.7; 157.6; 143.9; 141.4; 140.3; 138.2; 
137.3; 131.3; 131.0; 130.6; 129.9; 129.6; 129.2; 126.2; 120.4; 119.2; 118.2; 117.0; 111.9; 101.6; 
67.1; 54.1; 52.0; 51.0; 9.6. Anal. Calc. For C28H26ClN5O6S · 2 HCl  C% 50.27, H% 4.22, N% 
10.47; found C% 50.29, H% 4.23, N% 10.27. 
 
3.3. Dissociation constants determination 
The ionisation constants of compounds were determined by potentiometric titration with the 
GLpKa apparatus (Sirius Analytical Instruments Ltd, Forrest Row, East Sussex, UK). Apparent 
ionisation constants (psKa) were obtained in co-solvent mixtures because of the low aqueous 
solubility of compounds according to the following procedure. At least five separate 20 mL 
semiaqueous solutions of the compounds (about 1 mM in 17-65 Wt% methanol for chloroquine 
derivatives and 40-65 Wt% methanol for amodiaquine derivatives) were initially acidified to pH 1.8 
with 0.5 N HCl. The solutions were then titrated with standardised 0.5 N KOH to pH 10.5. The 
titrations were performed under argon at 25.0  0.1 °C. The initial estimates of the apparent 
ionisation constants (psKa) were obtained by Bjerrum plots; these values were finally refined by a 
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weighted non-linear least-squares procedure. Aqueous pKa values were obtained by extrapolation 
using the Yasuda-Shedlovsky procedure [31]. The molar % of species were calculated using the 
experimental pKa values from the Henderson-Hasselbalch equation. 
 
3.4.1 Parasite cultures 
P. falciparum cultures were carried out according to Trager and Jensen’s with slight modifications 
[32]. The CQ-sensitive, strain D10 and the CQ-resistant, strain W2 were maintained at 5 % 
hematocrit (human type A-positive red blood cells) in RPMI 1640 (EuroClone, Celbio) medium 
with the addition of 1% AlbuMax (Invitrogen, Milan, Italy), 0.01% hypoxantine, 20 mM Hepes, 
and 2 mM glutammine. All the cultures were maintained at 37 °C in a standard gas mixture 
consisting of 1% O2, 5% CO2, 94% N2.  
 
3.4.2 Parasite growth and drug susceptibility assay  
Compounds were dissolved in either water (chloroquine) or DMSO and then diluted with medium 
to achieve the required concentrations (final DMSO concentration <1 %, which is non-toxic to the 
parasite). Drugs were placed in 96 wells flat-bottom microplates (COSTAR) and serial dilutions 
made. Asynchronous cultures with parasitemia of 1-1.5 % and 1 % final haematocrit were aliquoted 
into the plates and incubated for 72 hours at 37 °C. Parasite growth was determined 
spectrophotometrically (OD650) by measuring the activity of the parasite lactate dehydrogenase 
(pLDH), according to a modified version of Makler’s method in control and drug-treated cultures 
[33,34]. Antimalarial activity is expressed as the 50 % inhibitory concentrations (IC50); each IC50 
value is the mean and standard deviation of at least three separate experiments. 
 
3.4.3. Vasodilator activity assay.  
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Thoracic aortas were isolated from male Wistar rats weighing 180-200 g. The endothelium was 
removed and the vessels were elically cut: three strips were obtained from each aorta. The tissues 
were mounted in organ baths containing 30 mL of  Krebs-bicarbonate buffer of the following 
composition (mM): NaCl 111.2, KCl 5.0, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.0, NaHCO3 12, glucose 
11.1 maintained at 37 °C and continuously gassed with 95% O2-5% CO2 (pH=7.4). The aortic strips 
were allowed to equilibrate for 90 min and then contracted with 1 M (-) phenylephrine. When the 
response to the agonist reached a plateau, cumulative concentration–response curves were 
determined. Effect of 1 M ODQ was evaluated in separate series of experiments in which they was 
added 5 min before the contraction. EC50 values are the mean of at least 5 determinations. 
Responses were recorded by an isometric transducer connected to the MacLab System PowerLab. 
 
3.4.4.Mice, infection and treatment  
Six to eight week old C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor, ME). 
All experimental protocols were reviewed and approved by LJBI Institutional Animal Care and Use 
Committee. Plasmodium berghei ANKA strain expressing the green fluorescent protein (PbA-GFP, 
a kind donation of MR4, Manassas, VA) was inoculated intraperitoneally (1x10
6
 parasitized red 
blood cells) and parasitemia, motor behavior, rectal temperature and weight were checked 
beginning on day 5 after infection. CM was defined as the presentation of one or more of the 
following clinical signs of neurological involvement: ataxia, limb paralysis, poor righting reflex, 
seizures, roll-over, coma. Additional clinical evaluation was performed using a set of six simple 
behavioral tests, as described [18]. Mice with late stage CM were treated with either amodiaquine 
(AQ) at 1mg per mouse, compound 40 or compound 31 at molar-equivalent doses (1.4mg and 
1.15mg per mouse, respectively) daily for 5 days. Compound 40 was prepared in vehicle 
containaing 20% DMSO (Sigma, St Louis, MO), 20% polyethyleneglycol 400 (Sigma) and 60% 
saline, and compound 31 was prepared in saline. AQ was given in the control group in the same 
vehicle as the test compound. Each mouse received 100µL intraperitoneally. 
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Figure Captions 
 
Scheme 1. Preparation of derivatives 3, 4, 7, 12-15. Reagents and conditions: (a) fuming HNO3, -15 
°C to RT, 24 h; (b) EtNH2, EtOH, RT; 48 h; (c) 1N HCl; (d) ion-exchange chromatography, 
Amberlite IRA-400. 
 
Scheme 2. Preparation of 26. Reagents and conditions: (a) CH3SO2Cl, Et3N, CH2Cl2, RT; (b) 
potassium phtalimide, KI cat., CH3CN, reflux, 72 h. (c) KMnO4, Acetone/H2O, 0 °C to RT, 3 h; (d) 
Acetone, PPTS cat, RT, 18 h; (e) N2H4 
.
 H2O, dist. THF, reflux, 24 h; (f) 2-nitrobenzensulfonyl 
chloride, Et3N, CH2Cl2, 0 °C to RT, 30 min; (g) EtI, K2CO3, DMF, 60 °C, 10 h; (h) PhSH, KOH, 
CH3CN,  0 °C to 50 °C, 4 h, N2 atmosphere. (i) CF3COOH/H2O 8/2, reflux, 24 h; (j) ion-exchange 
chromatography, Amberlite IRA-400; (k) fuming HNO3, -15 °C to RT, 40 h. 
 
Scheme 3. Preparation of derivatives 28-35. Reagents and conditions: (a) 3, 4, 7, 26, Et3N, CH3CN/ 
DMF 1/1, RT, 6 h; (b) HCl satd Et2O, MeOH; (c) 12-15, Et3N, CH3CN/ DMF 1/1, RT, 6 h. 
 
Scheme 4. Preparation of derivatives 37, 40. Reagents and conditions: (a) 2-(ethylamino)ethanol, 
CH3CN, RT, 20 h; (b) 3-phenyl-4-benzenesulfonyl furoxan, 50% aq NaOH, dist. THF/DMF, RT, 
N2 atmosphere (c) 39, Et3N, iPrOH/DMF, RT, 24 h; (d) 2-(ethylamino)ethanol, 50% aq NaOH, dist. 
THF/DMF, RT, 20 h; N2 atmosphere.  
 
Figure 1. Efficacy of amodiaquine (AQ), compound 40 and compound 31 in rescuing mice with 
late stage CM. A and B: survival curves of of PbA-infected mice with late stage CM following 
treatment with: (A) AQ (solid circle) 1 mg per mouse (n = 12) or compound 40 (open square, 
dashed line) at an equivalent molar dose (1.4 mg per mouse, n = 12) and; (B) AQ (solid circle) 1 mg 
per mouse (n = 29) or compound 31 (open triangle, dashed line) also at an equivalent molar dose 
(1.15 mg per mouse, n = 19). C and D: parasitemia curves showing the profile of parasite clearance 
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of the same treatment groups showed in A and B, respectively. Results in C and D are the mean ± 
SEM. 
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Table 1. Dissociation constants of the final compounds 
Compound pKa1
a
 pKa2
a
 pKa3
a
 
28 7.42 8.47 - 
29 7.06 8.14 - 
30 7.08 8.56 - 
31 6.99 8.09 - 
32 7.08 7.86 - 
33 7.05 7.98 - 
34 3.00 6.46 7.59 
35 3.06 6.71 7.69 
37 6.18 7.66 - 
40 6.12 7.68 - 
a
 Determined by potentiometry; S.D. ≤ 0.07. 
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Table 2. Antiplasmodial action and vasodilating ability of the synthesised compounds and reference 
derivatives 
 
Compound D10 (CQ-S) 
IC50 (M)
a
  
W2 (CQ-R) 
IC50 (M)
a
 
EC50 (M)
b
 
 
EC50 (M)
b
 
+ ODQ 1 M 
28 0.027  0.012 0.062  0.027 0.42  0.09 11  1 
29 0.027  0.016 0.031  0.013 0.45  0.12 3.3  0.8 
30 0.031  0.012 0.028  0.013 0.45  0.05 > 30
c
 
31 0.038  0.007 0.021  0.004 0.22  0.04 > 30
c
 
32 0.019  0.007 0.028  0.008 0.10  0.04 > 30
c
 
33 0.019  0.001 0.025  0.012 0.10  0.02 > 30
c
 
34 0.055  0.007 0.138  0.028 0.12  0.02 6.5  0.8 
35 0.018  0.003 0.034  0.017 0.079  0.012 3.6  0.4 
37 0.023  0.005 0.024  0.003 1.2  0.2 > 10
c
 
40 0.046  0.029 0.152  0.075 0.017  0.003 1.0  0.1 
     
3 > 5 > 5 - - 
7 > 5 > 5 - - 
12 > 5 > 5 - - 
13 > 5 > 5 - - 
14 > 5 > 5 - - 
15 > 5 > 5 - - 
26 > 5 > 5 - - 
O
N
+
N
SON
O O
O  
A  
 
> 5 
 
> 5 
 
14.3  3.8 
 
> 10
c
 
O
N
+
N
ON
O  
B  
 
> 5 
 
4.94  2.03 
 
0.030  0.004 
 
- 
AQ 0.012  0.001 0.016  0.004 inactive inactive 
chloroquine 0.025  0.007 0.632  0.209 - - 
a
 The IC50 represents the μM equivalents of test compounds required to inhibit parasite growth by 
50% (data are expressed as mean  SD). 
b
 The EC50 represents the M equivalents of test compounds required to relax the precontracted rat 
aorta strips by 50% (data are expressed as means  SE). 
c
 not able to reach 50% tissue relaxation at the maximum concentration tested. 
- = not tested 
